Wip1 and p53 contribute to HTLV-1 Tax-induced tumorigenesis

Retrovirology

Volumn 9, Issue , 2012, Pages

  Zane, Linda ^a   Yasunaga, Junichiro ^b   Mitagami, Yu ^b   Yedavalli, Venkat ^a   Tang, Sai Wen ^a   Chen, Chia Yen ^a   Ratner, Lee ^c   Lu, Xiongbin ^d   Jeang, Kuan Teh ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b KYOTO UNIVERSITY   (Japan)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATASE; PROTEIN P53; TAX PROTEIN; UNCLASSIFIED DRUG; WIP1 PHOSPHATASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; GENE ACTIVATION; GENE EXPRESSION; GENE FUNCTION; GENE INACTIVATION; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS INFECTION; IN VIVO STUDY; LEUKEMOGENESIS; MOUSE; NONHUMAN; PREVALENCE; T CELL LEUKEMIA;

ANIMALS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CELL TRANSFORMATION, VIRAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE EXPRESSION REGULATION, VIRAL; GENE PRODUCTS, TAX; GENOTYPE; HUMANS; MICE; MICE, TRANSGENIC; NEOPLASMS; PHOSPHOPROTEIN PHOSPHATASES; PHOSPHORYLATION; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

HUMAN T-LYMPHOTROPIC VIRUS 1; MUS; MUS MUSCULUS;

EID: 84871368224     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-9-114     Document Type: Article

References (119)

1. Proietti FA, Carneiro-Proietti AB, Catalan-Soares BC, Murphy EL. Global epidemiology of HTLV-I infection and associated diseases. Oncogene 2005, 24(39):6058-6068. 10.1038/sj.onc.1208968, 16155612.
2. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A 1980, 77(12):7415-7419. 10.1073/pnas.77.12.7415, 350514, 6261256.
3. Hinuma Y, Nagata K, Hanaoka M, Nakai M, Matsumoto T, Kinoshita KI, Shirakawa S, Miyoshi I. Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc Natl Acad Sci U S A 1981, 78(10):6476-6480. 10.1073/pnas.78.10.6476, 349062, 7031654.
4. Miyoshi I, Kubonishi I, Yoshimoto S, Akagi T, Ohtsuki Y, Shiraishi Y, Nagata K, Hinuma Y. Type C virus particles in a cord T-cell line derived by co-cultivating normal human cord leukocytes and human leukaemic T cells. Nature 1981, 294(5843):770-771. 10.1038/294770a0, 6275274.
5. Yoshida M, Miyoshi I, Hinuma Y. Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc Natl Acad Sci U S A 1982, 79(6):2031-2035. 10.1073/pnas.79.6.2031, 346116, 6979048.
6. Watanabe T, Seiki M, Yoshida M. Retrovirus terminology. Science 1983, 222(4629):1178.
7. Gallo RC. History of the discoveries of the first human retroviruses: HTLV-1 and HTLV-2. Oncogene 2005, 24(39):5926-5930. 10.1038/sj.onc.1208980, 16155599.
8. Goncalves DU, Proietti FA, Barbosa-Stancioli EF, Martins ML, Ribas JG, Martins-Filho OA, Teixeira-Carvalho A, Peruhype-Magalhaes V, Carneiro-Proietti AB. HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) inflammatory network. Inflamm Allergy Drug Targets 2008, 7(2):98-107. 10.2174/187152808785107642, 18691139.
9. Gessain A, Mahieux R. Tropical spastic paraparesis and HTLV-1 associated myelopathy: clinical, epidemiological, virological and therapeutic aspects. Rev Neurol (Paris) 2012, 168(3):257-269.
10. Tanaka A, Takahashi C, Yamaoka S, Nosaka T, Maki M, Hatanaka M. Oncogenic transformation by the tax gene of human T-cell leukemia virus type I in vitro. Proc Natl Acad Sci U S A 1990, 87(3):1071-1075. 10.1073/pnas.87.3.1071, 53412, 2300570.
11. Zane L, Yasunaga J, Kinjo T, de Melo G, Jeang KT. Transformation of human embryonic stem cells by HTLV-1 Tax. Retrovirology 2011, 8(Suppl 1):A164.
12. Grassmann R, Berchtold S, Radant I, Alt M, Fleckenstein B, Sodroski JG, Haseltine WA, Ramstedt U. Role of human T-cell leukemia virus type 1 X region proteins in immortalization of primary human lymphocytes in culture. J Virol 1992, 66(7):4570-4575. 241270, 1351105.
13. Rosin O, Koch C, Schmitt I, Semmes OJ, Jeang KT, Grassmann R. A human T-cell leukemia virus Tax variant incapable of activating NF-kappaB retains its immortalizing potential for primary T-lymphocytes. J Biol Chem 1998, 273(12):6698-6703. 10.1074/jbc.273.12.6698, 9506967.
14. Nerenberg M, Hinrichs SH, Reynolds RK, Khoury G, Jay G. The tat gene of human T-lymphotropic virus type 1 induces mesenchymal tumors in transgenic mice. Science 1987, 237(4820):1324-1329. 10.1126/science.2888190, 2888190.
15. Grossman WJ, Kimata JT, Wong FH, Zutter M, Ley TJ, Ratner L. Development of leukemia in mice transgenic for the tax gene of human T-cell leukemia virus type I. Proc Natl Acad Sci U S A 1995, 92(4):1057-1061. 10.1073/pnas.92.4.1057, 42636, 7862633.
16. Hasegawa H, Sawa H, Lewis MJ, Orba Y, Sheehy N, Yamamoto Y, Ichinohe T, Tsunetsugu-Yokota Y, Katano H, Takahashi H, et al. Thymus-derived leukemia-lymphoma in mice transgenic for the Tax gene of human T-lymphotropic virus type I. Nat Med 2006, 12(4):466-472. 10.1038/nm1389, 16550188.
17. Ohsugi T, Kumasaka T, Okada S, Urano T. The Tax protein of HTLV-1 promotes oncogenesis in not only immature T cells but also mature T cells. Nat Med 2007, 13(5):527-528. 10.1038/nm0507-527, 17479090.
18. Grassmann R, Aboud M, Jeang KT. Molecular mechanisms of cellular transformation by HTLV-1 Tax. Oncogene 2005, 24(39):5976-5985. 10.1038/sj.onc.1208978, 16155604.
19. Matsuoka M, Jeang KT. Human T-cell leukemia virus type 1 (HTLV-1) and leukemic transformation: viral infectivity, Tax, HBZ and therapy. Oncogene 2011, 30(12):1379-1389. 10.1038/onc.2010.537, 3413891, 21119600.
20. Zane L, Sibon D, Jeannin L, Zandecki M, Delfau-Larue MH, Gessain A, Gout O, Pinatel C, Lancon A, Mortreux F, et al. Tax gene expression and cell cycling but not cell death are selected during HTLV-1 infection in vivo. Retrovirology 2010, 7:17. 10.1186/1742-4690-7-17, 2846874, 20222966.
21. Jeang KT, Boros I, Brady J, Radonovich M, Khoury G. Characterization of cellular factors that interact with the human T-cell leukemia virus type I p40x-responsive 21-base-pair sequence. J Virol 1988, 62(12):4499-4509. 253560, 3263510.
22. Goren I, Semmes OJ, Jeang KT, Moelling K. The amino terminus of Tax is required for interaction with the cyclic AMP response element binding protein. J Virol 1995, 69(9):5806-5811. 189446, 7637025.
23. Tie F, Adya N, Greene WC, Giam CZ. Interaction of the human T-lymphotropic virus type 1 Tax dimer with CREB and the viral 21-base-pair repeat. J Virol 1996, 70(12):8368-8374. 190925, 8970957.
24. Harrod R, Tang Y, Nicot C, Lu HS, Vassilev A, Nakatani Y, Giam CZ. An exposed KID-like domain in human T-cell lymphotropic virus type 1 Tax is responsible for the recruitment of coactivators CBP/p300. Mol Cell Biol 1998, 18(9):5052-5061. 109090, 9710589.
25. Harhaj EW, Sun SC. IKKgamma serves as a docking subunit of the IkappaB kinase (IKK) and mediates interaction of IKK with the human T-cell leukemia virus Tax protein. J Biol Chem 1999, 274(33):22911-22914. 10.1074/jbc.274.33.22911, 10438454.
26. Xiao G, Cvijic ME, Fong A, Harhaj EW, Uhlik MT, Waterfield M, Sun SC. Retroviral oncoprotein Tax induces processing of NF-kappaB2/p100 in T cells: evidence for the involvement of IKKalpha. EMBO J 2001, 20(23):6805-6815. 10.1093/emboj/20.23.6805, 125766, 11726516.
27. Iha H, Kibler KV, Yedavalli VR, Peloponese JM, Haller K, Miyazato A, Kasai T, Jeang KT. Segregation of NF-kappaB activation through NEMO/IKKgamma by Tax and TNFalpha: implications for stimulus-specific interruption of oncogenic signaling. Oncogene 2003, 22(55):8912-8923. 10.1038/sj.onc.1207058, 14654787.
28. Qu Z, Xiao G. Human T-cell lymphotropic virus: a model of NF-kappaB-associated tumorigenesis. Viruses 2011, 3(6):714-749. 10.3390/v3060714, 3131208,3131208, 21743832.
29. Fu DX, Kuo YL, Liu BY, Jeang KT, Giam CZ. Human T-lymphotropic virus type I tax activates I-kappa B kinase by inhibiting I-kappa B kinase-associated serine/threonine protein phosphatase 2A. J Biol Chem 2003, 278(3):1487-1493. 10.1074/jbc.M210631200, 12419799.
30. Iwanaga R, Ohtani K, Hayashi T, Nakamura M. Molecular mechanism of cell cycle progression induced by the oncogene product Tax of human T-cell leukemia virus type I. Oncogene 2001, 20(17):2055-2067. 10.1038/sj.onc.1204304, 11360190.
31. Haller K, Wu Y, Derow E, Schmitt I, Jeang KT, Grassmann R. Physical interaction of human T-cell leukemia virus type 1 Tax with cyclin-dependent kinase 4 stimulates the phosphorylation of retinoblastoma protein. Mol Cell Biol 2002, 22(10):3327-3338. 10.1128/MCB.22.10.3327-3338.2002, 133776, 11971966.
32. Fraedrich K, Muller B, Grassmann R. The HTLV-1 Tax protein binding domain of cyclin-dependent kinase 4 (CDK4) includes the regulatory PSTAIRE helix. Retrovirology 2005, 2:54. 10.1186/1742-4690-2-54, 1253534, 16164752.
33. Neuveut C, Low KG, Maldarelli F, Schmitt I, Majone F, Grassmann R, Jeang KT. Human T-cell leukemia virus type 1 Tax and cell cycle progression: role of cyclin D-cdk and p110Rb. Mol Cell Biol 1998, 18(6):3620-3632. 108944, 9584203.
34. Jeong SJ, Dasgupta A, Jung KJ, Um JH, Burke A, Park HU, Brady JN. PI3K/AKT inhibition induces caspase-dependent apoptosis in HTLV-1-transformed cells. Virology 2008, 370(2):264-272. 10.1016/j.virol.2007.09.003, 2189985, 17931677.
35. Liu Y, Wang Y, Yamakuchi M, Masuda S, Tokioka T, Yamaoka S, Maruyama I, Kitajima I. Phosphoinositide-3 kinase-PKB/Akt pathway activation is involved in fibroblast Rat-1 transformation by human T-cell leukemia virus type I tax. Oncogene 2001, 20(20):2514-2526. 10.1038/sj.onc.1204364, 11420661.
36. Peloponese JM, Jeang KT. Role for Akt/protein kinase B and activator protein-1 in cellular proliferation induced by the human T-cell leukemia virus type 1 tax oncoprotein. J Biol Chem 2006, 281(13):8927-8938. 10.1074/jbc.M510598200, 16436385.
37. Majone F, Semmes OJ, Jeang KT. Induction of micronuclei by HTLV-I Tax: a cellular assay for function. Virology 1993, 193(1):456-459. 10.1006/viro.1993.1145, 8438579.
38. Semmes OJ, Majone F, Cantemir C, Turchetto L, Hjelle B, Jeang KT. HTLV-I and HTLV-II Tax: differences in induction of micronuclei in cells and transcriptional activation of viral LTRs. Virology 1996, 217(1):373-379. 10.1006/viro.1996.0126, 8599225.
39. Kinjo T, Ham-Terhune J, Peloponese JM, Jeang KT. Induction of reactive oxygen species by human T-cell leukemia virus type 1 tax correlates with DNA damage and expression of cellular senescence marker. J Virol 2010, 84(10):5431-5437. 10.1128/JVI.02460-09, 2863840, 20219913.
40. Majone F, Jeang KT. Unstabilized DNA breaks in HTLV-1 Tax expressing cells correlate with functional targeting of Ku80, not PKcs, XRCC4, or H2AX. Cell Biosci 2012, 2(1):15. 10.1186/2045-3701-2-15, 3448514, 22541714.
41. Durkin SS, Guo X, Fryrear KA, Mihaylova VT, Gupta SK, Belgnaoui SM, Haoudi A, Kupfer GM, Semmes OJ. HTLV-1 Tax oncoprotein subverts the cellular DNA damage response via binding to DNA-dependent protein kinase. J Biol Chem 2008, 283(52):36311-36320. 10.1074/jbc.M804931200, 2605996, 18957425.
42. Gatza ML, Dayaram T, Marriott SJ. Ubiquitination of HTLV-I Tax in response to DNA damage regulates nuclear complex formation and nuclear export. Retrovirology 2007, 4:95. 10.1186/1742-4690-4-95, 2234431, 18081936.
43. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000, 100(1):57-70. 10.1016/S0092-8674(00)81683-9, 10647931.
44. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674. 10.1016/j.cell.2011.02.013, 21376230.
45. Jin DY, Spencer F, Jeang KT. Human T cell leukemia virus type 1 oncoprotein Tax targets the human mitotic checkpoint protein MAD1. Cell 1998, 93(1):81-91. 10.1016/S0092-8674(00)81148-4, 9546394.
46. Yasunaga J, Jeang KT. Viral transformation and aneuploidy. Environ Mol Mutagen 2009, 50(8):733-740. 10.1002/em.20480, 2760603, 19326462.
47. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2002, 2(8):594-604. 10.1038/nrc864, 12154352.
48. Zenz T, Benner A, Dohner H, Stilgenbauer S. Chronic lymphocytic leukemia and treatment resistance in cancer: the role of the p53 pathway. Cell Cycle 2008, 7(24):3810-3814. 10.4161/cc.7.24.7245, 19098429.
49. Freed-Pastor WA, Prives C. Mutant p53: one name, many proteins. Genes Dev 2012, 26(12):1268-1286. 10.1101/gad.190678.112, 3387655, 22713868.
50. Xu-Monette ZY, Medeiros LJ, Li Y, Orlowski RZ, Andreeff M, Bueso-Ramos CE, Greiner TC, McDonnell TJ, Young KH. Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies. Blood 2012, 119(16):3668-3683. 10.1182/blood-2011-11-366062, 22275381.
51. Toyooka S, Tsuda T, Gazdar AF. The TP53 gene, tobacco exposure, and lung cancer. Hum Mutat 2003, 21(3):229-239. 10.1002/humu.10177, 12619108.
52. Iacopetta B. TP53 mutation in colorectal cancer. Hum Mutat 2003, 21(3):271-276. 10.1002/humu.10175, 12619112.
53. Hatta Y, Koeffler HP. Role of tumor suppressor genes in the development of adult T cell leukemia/lymphoma (ATLL). Leukemia 2002, 16(6):1069-1085. 10.1038/sj.leu.2402458, 12040438.
54. Tawara M, Hogerzeil SJ, Yamada Y, Takasaki Y, Soda H, Hasegawa H, Murata K, Ikeda S, Imaizumi Y, Sugahara K, et al. Impact of p53 aberration on the progression of Adult T-cell Leukemia/Lymphoma. Cancer Lett 2006, 234(2):249-255. 10.1016/j.canlet.2005.03.039, 15896902.
55. Tabakin-Fix Y, Azran I, Schavinky-Khrapunsky Y, Levy O, Aboud M. Functional inactivation of p53 by human T-cell leukemia virus type 1 Tax protein: mechanisms and clinical implications. Carcinogenesis 2006, 27(4):673-681.
56. Nagai H, Kinoshita T, Imamura J, Murakami Y, Hayashi K, Mukai K, Ikeda S, Tobinai K, Saito H, Shimoyama M, et al. Genetic alteration of p53 in some patients with adult T-cell leukemia. Jpn J Cancer Res 1991, 82(12):1421-1427. 10.1111/j.1349-7006.1991.tb01815.x, 1778765.
57. Sakashita A, Hattori T, Miller CW, Suzushima H, Asou N, Takatsuki K, Koeffler HP. Mutations of the p53 gene in adult T-cell leukemia. Blood 1992, 79(2):477-480.
58. Reid RL, Lindholm PF, Mireskandari A, Dittmer J, Brady JN. Stabilization of wild-type p53 in human T-lymphocytes transformed by HTLV-I. Oncogene 1993, 8(11):3029-3036.
59. Pise-Masison CA, Choi KS, Radonovich M, Dittmer J, Kim SJ, Brady JN. Inhibition of p53 transactivation function by the human T-cell lymphotropic virus type 1 Tax protein. J Virol 1998, 72(2):1165-1170. 124592, 9445014.
60. Pise-Masison CA, Radonovich M, Sakaguchi K, Appella E, Brady JN. Phosphorylation of p53: a novel pathway for p53 inactivation in human T-cell lymphotropic virus type 1-transformed cells. J Virol 1998, 72(8):6348-6355. 109779, 9658074.
61. Akagi T, Ono H, Tsuchida N, Shimotohno K. Aberrant expression and function of p53 in T-cells immortalized by HTLV-I Tax1. FEBS Lett 1997, 406(3):263-266. 10.1016/S0014-5793(97)00280-9, 9136898.
62. Ariumi Y, Kaida A, Lin JY, Hirota M, Masui O, Yamaoka S, Taya Y, Shimotohno K. HTLV-1 tax oncoprotein represses the p53-mediated trans-activation function through coactivator CBP sequestration. Oncogene 2000, 19(12):1491-1499. 10.1038/sj.onc.1203450, 10734308.
63. Pise-Masison CA, Mahieux R, Radonovich M, Jiang H, Brady JN. Human T-lymphotropic virus type I Tax protein utilizes distinct pathways for p53 inhibition that are cell type-dependent. J Biol Chem 2001, 276(1):200-205.
64. Van PL, Yim KW, Jin DY, Dapolito G, Kurimasa A, Jeang KT. Genetic evidence of a role for ATM in functional interaction between human T-cell leukemia virus type 1 Tax and p53. J Virol 2001, 75(1):396-407. 10.1128/JVI.75.1.396-407.2001, 113932, 11119608.
65. Miyazato A, Sheleg S, Iha H, Li Y, Jeang KT. Evidence for NF-kappaB- and CBP-independent repression of p53's transcriptional activity by human T-cell leukemia virus type 1 Tax in mouse embryo and primary human fibroblasts. J Virol 2005, 79(14):9346-9350. 10.1128/JVI.79.14.9346-9350.2005, 1168794, 15994832.
66. Pise-Masison CA, Mahieux R, Jiang H, Ashcroft M, Radonovich M, Duvall J, Guillerm C, Brady JN. Inactivation of p53 by human T-cell lymphotropic virus type 1 Tax requires activation of the NF-kappaB pathway and is dependent on p53 phosphorylation. Mol Cell Biol 2000, 20(10):3377-3386. 10.1128/MCB.20.10.3377-3386.2000, 85630, 10779327.
67. Jeong SJ, Radonovich M, Brady JN, Pise-Masison CA. HTLV-I Tax induces a novel interaction between p65/RelA and p53 that results in inhibition of p53 transcriptional activity. Blood 2004, 104(5):1490-1497. 10.1182/blood-2003-12-4174, 15155458.
68. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT, Weinberg RA. Tumor spectrum analysis in p53-mutant mice. Curr Biol 1994, 4(1):1-7. 10.1016/S0960-9822(00)00002-6, 7922305.
69. Chi YH, Ward JM, Cheng LI, Yasunaga J, Jeang KT. Spindle assembly checkpoint and p53 deficiencies cooperate for tumorigenesis in mice. Int J Cancer 2009, 124(6):1483-1489. 10.1002/ijc.24094, 2706662, 19065665.
70. Fiscella M, Zhang H, Fan S, Sakaguchi K, Shen S, Mercer WE, Vande Woude GF, O'Connor PM, Appella E. Wip1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner. Proc Natl Acad Sci U S A 1997, 94(12):6048-6053. 10.1073/pnas.94.12.6048, 20998, 9177166.
71. Bulavin DV, Demidov ON, Saito S, Kauraniemi P, Phillips C, Amundson SA, Ambrosino C, Sauter G, Nebreda AR, Anderson CW, et al. Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat Genet 2002, 31(2):210-215. 10.1038/ng894, 12021785.
72. Yu E, Ahn YS, Jang SJ, Kim MJ, Yoon HS, Gong G, Choi J. Overexpression of the wip1 gene abrogates the p38 MAPK/p53/Wip1 pathway and silences p16 expression in human breast cancers. Breast Cancer Res Treat 2007, 101(3):269-278. 10.1007/s10549-006-9304-y, 16897432.
73. el-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B. Definition of a consensus binding site for p53. Nat Genet 1992, 1(1):45-49. 10.1038/ng0492-45, 1301998.
74. Choi J, Nannenga B, Demidov ON, Bulavin DV, Cooney A, Brayton C, Zhang Y, Mbawuike IN, Bradley A, Appella E, et al. Mice deficient for the wild-type p53-induced phosphatase gene (Wip1) exhibit defects in reproductive organs, immune function, and cell cycle control. Mol Cell Biol 2002, 22(4):1094-1105. 10.1128/MCB.22.4.1094-1105.2002, 134641, 11809801.
75. Waldele K, Silbermann K, Schneider G, Ruckes T, Cullen BR, Grassmann R. Requirement of the human T-cell leukemia virus (HTLV-1) tax-stimulated HIAP-1 gene for the survival of transformed lymphocytes. Blood 2006, 107(11):4491-4499. 10.1182/blood-2005-08-3138, 16467195.
76. Pichler K, Kattan T, Gentzsch J, Kress AK, Taylor GP, Bangham CR, Grassmann R. Strong induction of 4-1BB, a growth and survival promoting costimulatory receptor, in HTLV-1-infected cultured and patients' T cells by the viral Tax oncoprotein. Blood 2008, 111(9):4741-4751. 10.1182/blood-2007-10-115220, 18276843.
77. Krueger A, Fas SC, Giaisi M, Bleumink M, Merling A, Stumpf C, Baumann S, Holtkotte D, Bosch V, Krammer PH, et al. HTLV-1 Tax protects against CD95-mediated apoptosis by induction of the cellular FLICE-inhibitory protein (c-FLIP). Blood 2006, 107(10):3933-3939. 10.1182/blood-2005-06-2567, 16403915.
78. Jeang KT, Widen SG, Semmes OJ, Wilson SH. HTLV-I trans-activator protein, tax, is a trans-repressor of the human beta-polymerase gene. Science 1990, 247(4946):1082-1084. 10.1126/science.2309119, 2309119.
79. Zhang J, Yamada O, Kida S, Matsushita Y, Yamaoka S, Chagan-Yasutan H, Hattori T. Identification of CD44 as a downstream target of noncanonical NF-kappaB pathway activated by human T-cell leukemia virus type 1-encoded Tax protein. Virology 2011, 413(2):244-252. 10.1016/j.virol.2011.02.021, 21411116.
80. Zane L, Sibon D, Legras C, Lachuer J, Wierinckx A, Mehlen P, Delfau-Larue MH, Gessain A, Gout O, Pinatel C, et al. Clonal expansion of HTLV-1 positive CD8+ cells relies on cIAP-2 but not on c-FLIP expression. Virology 2010, 407(2):341-351. 10.1016/j.virol.2010.07.023, 20863547.
81. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW, Vogelstein B. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998, 282(5393):1497-1501.
82. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000, 408(6810):307-310. 10.1038/35042675, 11099028.
83. Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 2007, 26(15):2157-2165. 10.1038/sj.onc.1210302, 17401424.
84. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, Olivier M. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 2007, 28(6):622-629. 10.1002/humu.20495, 17311302.
85. Levine AJ, Oren M. The first 30 years of p53: growing ever more complex. Nat Rev Cancer 2009, 9(10):749-758. 10.1038/nrc2723, 2771725, 19776744.
86. Polager S, Ginsberg D. p53 and E2f: partners in life and death. Nat Rev Cancer 2009, 9(10):738-748. 10.1038/nrc2718, 19776743.
87. Poyurovsky MV, Prives C. Unleashing the power of p53: lessons from mice and men. Genes Dev 2006, 20(2):125-131. 10.1101/gad.1397506, 16418478.
88. Manfredi JJ. The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor. Genes Dev 2010, 24(15):1580-1589. 10.1101/gad.1941710, 2912554, 20679392.
89. Marine JC, Lozano G. Mdm2-mediated ubiquitylation: p53 and beyond. Cell Death Differ 2010, 17(1):93-102. 10.1038/cdd.2009.68, 19498444.
90. Piccinin S, Tonin E, Sessa S, Demontis S, Rossi S, Pecciarini L, Zanatta L, Pivetta F, Grizzo A, Sonego M, et al. A " Twist box" Code of p53 Inactivation: Twist box:p53 Interaction Promotes p53 Degradation. Cancer Cell 2012, 22(3):404-415. 10.1016/j.ccr.2012.08.003, 22975381.
91. Levine AJ. The common mechanisms of transformation by the small DNA tumor viruses: the inactivation of tumor suppressor gene products: p53. Virology 2009, 384(2):285-293. 10.1016/j.virol.2008.09.034, 19081592.
92. Atkin SJ, Griffin BE, Dilworth SM. Polyoma virus and simian virus 40 as cancer models: history and perspectives. Semin Cancer Biol 2009, 19(4):211-217. 10.1016/j.semcancer.2009.03.001, 19505648.
93. Gao P, Zheng J. Oncogenic virus-mediated cell fusion: new insights into initiation and progression of oncogenic viruses-related cancers. Cancer Lett 2011, 303(1):1-8. 10.1016/j.canlet.2010.12.021, 21306823.
94. Portis T, Grossman WJ, Harding JC, Hess JL, Ratner L. Analysis of p53 inactivation in a human T-cell leukemia virus type 1 Tax transgenic mouse model. J Virol 2001, 75(5):2185-2193. 10.1128/JVI.75.5.2185-2193.2001, 114802, 11160722.
95. Bulavin DV, Phillips C, Nannenga B, Timofeev O, Donehower LA, Anderson CW, Appella E, Fornace AJ. Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16(Ink4a)-p19(Arf) pathway. Nat Genet 2004, 36(4):343-350. 10.1038/ng1317, 14991053.
96. Shreeram S, Hee WK, Demidov ON, Kek C, Yamaguchi H, Fornace AJ, Anderson CW, Appella E, Bulavin DV. Regulation of ATM/p53-dependent suppression of myc-induced lymphomas by Wip1 phosphatase. J Exp Med 2006, 203(13):2793-2799. 10.1084/jem.20061563, 2118180, 17158963.
97. Demidov ON, Timofeev O, Lwin HN, Kek C, Appella E, Bulavin DV. Wip1 phosphatase regulates p53-dependent apoptosis of stem cells and tumorigenesis in the mouse intestine. Cell Stem Cell 2007, 1(2):180-190. 10.1016/j.stem.2007.05.020, 18371349.
98. Nannenga B, Lu X, Dumble M, Van Maanen M, Nguyen TA, Sutton R, Kumar TR, Donehower LA. Augmented cancer resistance and DNA damage response phenotypes in PPM1D null mice. Mol Carcinog 2006, 45(8):594-604. 10.1002/mc.20195, 16652371.
99. Lu X, Nguyen TA, Moon SH, Darlington Y, Sommer M, Donehower LA. The type 2C phosphatase Wip1: an oncogenic regulator of tumor suppressor and DNA damage response pathways. Cancer Metastasis Rev 2008, 27(2):123-135. 10.1007/s10555-008-9127-x, 2362138, 18265945.
100. Demidov ON, Kek C, Shreeram S, Timofeev O, Fornace AJ, Appella E, Bulavin DV. The role of the MKK6/p38 MAPK pathway in Wip1-dependent regulation of ErbB2-driven mammary gland tumorigenesis. Oncogene 2007, 26(17):2502-2506. 10.1038/sj.onc.1210032, 17016428.
101. Li J, Yang Y, Peng Y, Austin RJ, van Eyndhoven WG, Nguyen KC, Gabriele T, McCurrach ME, Marks JR, Hoey T, et al. Oncogenic properties of PPM1D located within a breast cancer amplification epicenter at 17q23. Nat Genet 2002, 31(2):133-134. 10.1038/ng888, 12021784.
102. Sinclair CS, Rowley M, Naderi A, Couch FJ. The 17q23 amplicon and breast cancer. Breast Cancer Res Treat 2003, 78(3):313-322. 10.1023/A:1023081624133, 12755490.
103. Barlund M, Kuukasjarvi T, Syrjakoski K, Auvinen A, Kallioniemi A. Frequent amplification and overexpression of CCND1 in male breast cancer. Int J Cancer 2004, 111(6):968-971. 10.1002/ijc.20307, 15300811.
104. Tan DS, Lambros MB, Rayter S, Natrajan R, Vatcheva R, Gao Q, Marchio C, Geyer FC, Savage K, Parry S, et al. PPM1D is a potential therapeutic target in ovarian clear cell carcinomas. Clin Cancer Res 2009, 15(7):2269-2280. 10.1158/1078-0432.CCR-08-2403, 19293255.
105. Natrajan R, Lambros MB, Rodriguez-Pinilla SM, Moreno-Bueno G, Tan DS, Marchio C, Vatcheva R, Rayter S, Mahler-Araujo B, Fulford LG, et al. Tiling path genomic profiling of grade 3 invasive ductal breast cancers. Clin Cancer Res 2009, 15(8):2711-2722. 10.1158/1078-0432.CCR-08-1878, 19318498.
106. Saito-Ohara F, Imoto I, Inoue J, Hosoi H, Nakagawara A, Sugimoto T, Inazawa J. PPM1D is a potential target for 17q gain in neuroblastoma. Cancer Res 2003, 63(8):1876-1883.
107. Castellino RC, De Bortoli M, Lu X, Moon SH, Nguyen TA, Shepard MA, Rao PH, Donehower LA, Kim JY. Medulloblastomas overexpress the p53-inactivating oncogene WIP1/PPM1D. J Neurooncol 2008, 86(3):245-256. 10.1007/s11060-007-9470-8, 2174521, 17932621.
108. Mendrzyk F, Radlwimmer B, Joos S, Kokocinski F, Benner A, Stange DE, Neben K, Fiegler H, Carter NP, Reifenberger G, et al. Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma. J Clin Oncol 2005, 23(34):8853-8862. 10.1200/JCO.2005.02.8589, 16314645.
109. Ehrbrecht A, Muller U, Wolter M, Hoischen A, Koch A, Radlwimmer B, Actor B, Mincheva A, Pietsch T, Lichter P, et al. Comprehensive genomic analysis of desmoplastic medulloblastomas: identification of novel amplified genes and separate evaluation of the different histological components. J Pathol 2006, 208(4):554-563. 10.1002/path.1925, 16400626.
110. Hirasawa A, Saito-Ohara F, Inoue J, Aoki D, Susumu N, Yokoyama T, Nozawa S, Inazawa J, Imoto I. Association of 17q21-q24 gain in ovarian clear cell adenocarcinomas with poor prognosis and identification of PPM1D and APPBP2 as likely amplification targets. Clin Cancer Res 2003, 9(6):1995-2004.
111. Fuku T, Semba S, Yutori H, Yokozaki H. Increased wild-type p53-induced phosphatase 1 (Wip1 or PPM1D) expression correlated with downregulation of checkpoint kinase 2 in human gastric carcinoma. Pathol Int 2007, 57(9):566-571. 10.1111/j.1440-1827.2007.02140.x, 17685927.
112. Loukopoulos P, Shibata T, Katoh H, Kokubu A, Sakamoto M, Yamazaki K, Kosuge T, Kanai Y, Hosoda F, Imoto I, et al. Genome-wide array-based comparative genomic hybridization analysis of pancreatic adenocarcinoma: identification of genetic indicators that predict patient outcome. Cancer Sci 2007, 98(3):392-400. 10.1111/j.1349-7006.2007.00395.x, 17233815.
113. Rauta J, Alarmo EL, Kauraniemi P, Karhu R, Kuukasjarvi T, Kallioniemi A. The serine-threonine protein phosphatase PPM1D is frequently activated through amplification in aggressive primary breast tumours. Breast Cancer Res Treat 2006, 95(3):257-263. 10.1007/s10549-005-9017-7, 16254685.
114. Martin F, Bangham CR, Ciminale V, Lairmore MD, Murphy EL, Switzer WM, Mahieux R. Conference highlights of the 15th International Conference on Human Retrovirology: HTLV and related retroviruses, 4-8 June 2011, Leuven, Gembloux, Belgium. Retrovirology 2011, 8:86. 10.1186/1742-4690-8-86, 3223150, 22035054.
115. Hayashi R, Tanoue K, Durell SR, Chatterjee DK, Jenkins LM, Appella DH, Appella E. Optimization of a cyclic peptide inhibitor of Ser/Thr phosphatase PPM1D (Wip1). Biochemistry 2011, 50(21):4537-4549. 10.1021/bi101949t, 3508689, 21528848.
116. Kern SE, Pietenpol JA, Thiagalingam S, Seymour A, Kinzler KW, Vogelstein B. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 1992, 256(5058):827-830. 10.1126/science.1589764, 1589764.
117. Choi J, Appella E, Donehower LA. The structure and expression of the murine wildtype p53-induced phosphatase 1 (Wip1) gene. Genomics 2000, 64(3):298-306. 10.1006/geno.2000.6134, 10756097.
118. Yamano Y, Nagai M, Brennan M, Mora CA, Soldan SS, Tomaru U, Takenouchi N, Izumo S, Osame M, Jacobson S. Correlation of human T-cell lymphotropic virus type 1 (HTLV-1) mRNA with proviral DNA load, virus-specific CD8(+) T cells, and disease severity in HTLV-1-associated myelopathy (HAM/TSP). Blood 2002, 99(1):88-94. 10.1182/blood.V99.1.88, 11756157.
119. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25(4):402-408. 10.1006/meth.2001.1262, 11846609.